**Table S2. Procedural codes for DMTs administered in the clinical setting.**

|  |  |
| --- | --- |
| **DMT** | **Procedural code** |
| Fingolimod | N/A |
| GA | Q2010 (terminated 12/31/2003; injection, GA, per dose)  J1595 (injection, GA, 20 mg) |
| Natalizumab | C9126 (terminated 3/31/2005; injection, natalizumab, per 5 mg)  J2323 (injection, natalizumab, 1 mg)  Q4079 (terminated 12/31/2007; injection, natalizumab, 1 mg) |
| IFN beta-1a | Q3025 (injection, IFN beta-1a, 11 µg for intramuscular use)  Q3026 (injection, IFN beta-1a, 11 µg for subcutaneous use)  J1825 (terminated 12/31/2010; injection, IFN beta-1a, 33 µg)  J1826 (injection, IFN beta-1a, 30 µg) |
| IFN beta-1b | J1830 (injection IFN beta-1b, 0.25 mg [code may be used for Medicare when drug is administered under the direct supervision of a physician, not for use when drug is self-administered]) |